TargetMol

LCAHA

Product Code:
 
TAR-T27804
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T27804-5mg5mg£337.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27804-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27804-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
LCAHA is a USP2a inhibitor. LCAHA inhibits growth of cyclin D1-dependent cells.
CAS:
117094-40-3
Formula:
C24H41NO3
Molecular Weight:
391.596
Purity:
0.98
SMILES:
[H][C@@]12CC[C@H]([C@H](C)CCC(=O)NO)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2C[C@H](O)CC[C@]12C

References

1. Samec P, Caha J, Zapletal M, Tu?ek P, Cudl?n P, Ku?era M. Discrimination between acute and chronic decline of Central European forests using map algebra of the growth condition and forest biomass fuzzy sets: A case study. Sci Total Environ. 2017 May 10;599-600:899-909. doi: 10.1016/j.scitotenv.2017.05.023. [Epub ahead of print] PubMed PMID: 28501014. 2. Zelen?k K, Walderov? R, Ku?ov? H, Jan?atov? D, Kom?nek P. Comparison of long-term voice outcomes after vocal fold augmentation using autologous fat injection by direct microlaryngoscopy versus office-based calcium hydroxylapatite injection. Eur Arch Otorhinolaryngol. 2017 May 6. doi: 10.1007/s00405-017-4600-1. [Epub ahead of print] PubMed PMID: 28478500. 3. Kadouch JA. Calcium hydroxylapatite: A review on safety and complications. J Cosmet Dermatol. 2017 Mar 1. doi: 10.1111/jocd.12326. [Epub ahead of print] Review. PubMed PMID: 28247924. 4. Yutskovskaya YA, Kogan EA. Improved Neocollagenesis and Skin Mechanical Properties After Injection of Diluted Calcium Hydroxylapatite in the Neck and De?colletage:A Pilot Study. J Drugs Dermatol. 2017 Jan 1;16(1):68-74. PubMed PMID: 28095536.